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NDRG1 (N-myc downstream regulated 1) was 
identified as a 5' fusion partner to ERG (v-ets 
erythroblastosis virus E26 oncogene homolog (avian)) 
by use of next-generation RNA sequencing (Pflueger t 
al., 2009). 




Prostate cancer is a hormonally sensitive cancer at arly 
stages and eventually becomes hormonally independent 
as it progresses to castration-resistant prostate cncer 
(CRPCa). All 5' fusion partners to ERG described in 
prostate cancer to date (TMPRSS2, SLC45A3, 
NDRG1, HERPUD1, FKBP5) are known androgen-
regulated genes. By utilizing androgen-responsive 
"promoters" as 5' partners, the fusion event drives th  
upregulation of the oncogene ERG. 
Estrogen signaling on TMPRSS2 (Setlur et al., 2008), 
SLC45A3 and NDRG1 (Pflueger et al., 2009) has been 
observed as an additional level of hormonal regulation. 
This aspect of ERG fusions in prostate cancer becoms 
more important in sight of the androgen hormone 
ablation treatment, leading to CRPCa. 
Epidemiology 
To date, two studies describe NDRG1-ERG fusion in a 
total of 3 prostate cancer cases with clinically localized  
disease (Pflueger et al., 2009; Esgueva et al., 2010). 
Pflueger et al. and Esgueva et al. estimate NDGR1 to 
be the 5' fusion partner in up to 5% of ERG-rearranged 
prostate cancer. In direct comparison, TMPRSS2 is the 
5' fusion partner in a majority (~78-82%) of ERG-
rearranged prostate cancer cases. SLC45A3 is the 5' 
partner to ERG in ~6-7% of rearrangement positive 
prostate cancer. Singular reports exist of a nonrecur ing 
ERG fusion with HERPUD1 (Maher et al., 2009) and 
FKBP5 (Pflueger et al., 2011), respectively.  
None of the well known prostate cancer cell lines 
(LNCaP, VCaP, 22Rv1, PC-3, NCI-H660 and DU145) 
harbor an NDRG1-ERG fusion (Pflueger et al., 2009). 





NDRG1 (N-myc downstream regulated 1) is a 
multifunctional protein that is ubiquitously express d in 
several tissues. It likely exerts its function cell type and 
tissue specific.  
It's described to act in stress response pathways, golgi
transport, cell cycle regulation and mitosis.  
It is hypothesized that it has a tumor-suppressive 
function in epithelial cells since lower expression levels 
have been observed in adenocarcinoma compared to 
normal tissue.  
Defects in this gene are found in a subtype of the 
Charcot-Marie-Tooth disease type 4D (CMT4D), a 
peripheral neuropathy. 
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ERG (v-ets erythroblastosis virus E26 oncogene like
(avian)) is a member of the ETS family of transcription 
factors. It is implicated in lymphoid cell development 
and endothelial cell differentiation, among other lss 
well described functions in mitogenic signal 
transduction pathways, platelet activation, DNA 
methylation, angiogenesis etc. Elevated ERG levels are 
observed in several disease conditions (i.e. several 
cancers, Alzheimer's disease, Down syndrome etc.). Its 
role in oncogenesis is well established since fusions 
between several genes and ERG are characteristic for 
Ewing sarcoma, acute myeloid leukemia and prostate 
cancer. 




The fusion breakpoint(s) on DNA level are unknown.  
However, there are at least 2 distinct transcript 
isoforms described (Pflueger et al., 2009) (see figure 
above): 
FJ627786: NDRG1 (NM_006096) exon 3 joined with 
ERG (NM_004449) exon 6. 
FJ627787: NDRG1 (NM_006096) exon 2 joined with 
ERG (NM_004449) exon 6. 
The exon junctions of NDRG1-ERG isoforms are 
utilizing the same splice sites as the respective wild-
type mRNAs possibly indicating the involvement of 




Unlike TMPRSS2-ERG and SLC45A3-ERG, the 
NDRG1-ERG gene fusion transcripts are in frame, 
meaning that NDRG1 contributes 33 (FJ627786) and 
21 (FJ627787) amino acids, respectively, to an 
NDRG1-ERG fusion protein (Pflueger et al., 2009). An 
antibody specific to NDRG1-ERG fusion protein does 
not exist yet. Hence, the expression of a fusion protein 
was indirectly verified by monitoring elevated ERG 
protein expression in cell lines that were transiently 
transfected with NDRG1-ERG expression vectors.  
In invasion assays, it was observed that NDRG1-ERG  
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confers increased invasiveness (unpublished results). 
Additional functions of the NDRG1-ERG fusion 
proteins have not been eluded further and it is unclear if 
they exert similar or differing functions compared to 
the N-terminally truncated ERG protein encoded by the 
TMPRSS2-ERG and SLC45A3-ERG fusions (Tomlins 
et al., 2008; Klezovitch et al., 2008). 
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